Annals of Internal Medicine: Giant Cell Arteritis/Polymyalgia Rheumatica Topic Collection

Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis A Randomized Trial

Hoffman GS, Cid MC, Rendt-Zagar KE, et al. — Tue, 01 May 2007 00:00:00 GMT

Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica A Randomized Trial

Salvarani C, Macchioni P, Manzini C, et al. — Tue, 01 May 2007 00:00:00 GMT

Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?

Luqmani R. — Tue, 01 May 2007 00:00:00 GMT

Giant cell arteritis (GCA) and polymyalgia rheumatica are common overlapping inflammatory rheumatic diseases of unknown cause that share some clinical features and affect patients older than 50 years. The age-adjusted annual incidence of GCA is 188 to 220 cases per 1 million persons (1, 2) in the United States and the United Kingdom and 290 per 1 million persons in Norway (3). The annual incidence of polymyalgia rheumatica varies from 120 per 1 million persons in Italy (4) to 1120 per million in Norway (3) and is higher in women than men.

Adding Infliximab to the Treatment Regimen for Giant Cell Arteritis

Tue, 01 May 2007 00:00:00 GMT

Adding Infliximab to the Treatment Regimen for Polymyalgia Rheumatica

Tue, 01 May 2007 00:00:00 GMT